Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Alteromonas macleodii tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG (mnmG), partial CSB-YP465563AZX
CSB-EP465563AZX
CSB-BP465563AZX
CSB-MP465563AZX
CSB-EP465563AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Urease subunit alpha (ureC), partial CSB-YP465564AZX
CSB-EP465564AZX
CSB-BP465564AZX
CSB-MP465564AZX
CSB-EP465564AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii 30S ribosomal protein S13 (rpsM) CSB-YP465565AZX
CSB-EP465565AZX
CSB-BP465565AZX
CSB-MP465565AZX
CSB-EP465565AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Arginine--tRNA ligase (argS), partial CSB-YP465566AZX
CSB-EP465566AZX
CSB-BP465566AZX
CSB-MP465566AZX
CSB-EP465566AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Na (+)/H (+) antiporter nhaB, partial CSB-YP465567AZX
CSB-EP465567AZX
CSB-BP465567AZX
CSB-MP465567AZX
CSB-EP465567AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Flagellar L-ring protein (flgH) CSB-YP465568AZX
CSB-EP465568AZX
CSB-BP465568AZX
CSB-MP465568AZX
CSB-EP465568AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Pyridoxine/pyridoxamine 5'-phosphate oxidase (pdxH) CSB-YP465569AZX
CSB-EP465569AZX
CSB-BP465569AZX
CSB-MP465569AZX
CSB-EP465569AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Membrane-bound lytic murein transglycosylase F (mltF) CSB-YP465570AZX
CSB-EP465570AZX
CSB-BP465570AZX
CSB-MP465570AZX
CSB-EP465570AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii N utilization substance protein B homolog (nusB) CSB-YP465571AZX
CSB-EP465571AZX
CSB-BP465571AZX
CSB-MP465571AZX
CSB-EP465571AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Regulator of ribonuclease activity B (rraB) CSB-YP465572AZX
CSB-EP465572AZX
CSB-BP465572AZX
CSB-MP465572AZX
CSB-EP465572AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Ribosome-binding factor A (rbfA) CSB-YP465573AZX
CSB-EP465573AZX
CSB-BP465573AZX
CSB-MP465573AZX
CSB-EP465573AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii 50S ribosomal protein L3 (rplC1) CSB-YP465574AZX
CSB-EP465574AZX
CSB-BP465574AZX
CSB-MP465574AZX
CSB-EP465574AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC) CSB-YP465575AZX
CSB-EP465575AZX
CSB-BP465575AZX
CSB-MP465575AZX
CSB-EP465575AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii 50S ribosomal protein L22 (rplV1) CSB-YP465576AZX
CSB-EP465576AZX
CSB-BP465576AZX
CSB-MP465576AZX
CSB-EP465576AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Protein-export protein secB (secB) CSB-YP465577AZX
CSB-EP465577AZX
CSB-BP465577AZX
CSB-MP465577AZX
CSB-EP465577AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Chaperone protein DnaK (dnaK), partial CSB-YP465578AZX
CSB-EP465578AZX
CSB-BP465578AZX
CSB-MP465578AZX
CSB-EP465578AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Sec-independent protein translocase protein TatA (tatA), partial CSB-YP465579AZX
CSB-EP465579AZX
CSB-BP465579AZX
CSB-MP465579AZX
CSB-EP465579AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Ketol-acid reductoisomerase (ilvC) CSB-YP465580AZX
CSB-EP465580AZX
CSB-BP465580AZX
CSB-MP465580AZX
CSB-EP465580AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Alteromonas macleodii Glycerol kinase (glpK) CSB-YP465581AZX
CSB-EP465581AZX
CSB-BP465581AZX
CSB-MP465581AZX
CSB-EP465581AZX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Prosthecochloris aestuarii DNA mismatch repair protein mutL (mutL), partial CSB-YP465582EYX
CSB-EP465582EYX
CSB-BP465582EYX
CSB-MP465582EYX
CSB-EP465582EYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>